WO2011149126A1 - Composition pharmaceutique comprenant un composé anti-inflammatoire présentant une fonction d'inhibition de la tyrosine kinase - Google Patents

Composition pharmaceutique comprenant un composé anti-inflammatoire présentant une fonction d'inhibition de la tyrosine kinase Download PDF

Info

Publication number
WO2011149126A1
WO2011149126A1 PCT/KR2010/003332 KR2010003332W WO2011149126A1 WO 2011149126 A1 WO2011149126 A1 WO 2011149126A1 KR 2010003332 W KR2010003332 W KR 2010003332W WO 2011149126 A1 WO2011149126 A1 WO 2011149126A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
tyrosine kinase
kinase inhibiting
inhibiting function
inflammatory compound
Prior art date
Application number
PCT/KR2010/003332
Other languages
English (en)
Korean (ko)
Inventor
양범석
김용주
박태교
우성호
이향숙
김선영
조종운
이홍범
Original Assignee
한국과학기술연구원
(주)레고켐바이오사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국과학기술연구원, (주)레고켐바이오사이언스 filed Critical 한국과학기술연구원
Priority to PCT/KR2010/003332 priority Critical patent/WO2011149126A1/fr
Priority to JP2013512543A priority patent/JP5613323B2/ja
Priority to CN201180026042.7A priority patent/CN102971327B/zh
Priority to US13/699,970 priority patent/US9062066B2/en
Priority to ES11786920.6T priority patent/ES2647586T3/es
Priority to DK11786920.6T priority patent/DK2578590T3/da
Priority to KR1020127030670A priority patent/KR101478302B1/ko
Priority to EP11786920.6A priority patent/EP2578590B1/fr
Priority to HUE11786920A priority patent/HUE035589T2/en
Priority to PCT/KR2011/003873 priority patent/WO2011149288A2/fr
Publication of WO2011149126A1 publication Critical patent/WO2011149126A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

La présente invention concerne une composition pharmaceutique qui contient un ingrédient actif sous forme d'un composé anti-inflammatoire présentant une fonction d'inhibition de la tyrosine kinase. Le composé selon la présente invention est en mesure de supprimer les activités de différentes tyrosine kinases. Il peut être utilisé avantageusement dans la prévention ou le traitement de maladies inflammatoires, de maladies auto-immunes et analogues qui y sont associées.
PCT/KR2010/003332 2010-05-26 2010-05-26 Composition pharmaceutique comprenant un composé anti-inflammatoire présentant une fonction d'inhibition de la tyrosine kinase WO2011149126A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
PCT/KR2010/003332 WO2011149126A1 (fr) 2010-05-26 2010-05-26 Composition pharmaceutique comprenant un composé anti-inflammatoire présentant une fonction d'inhibition de la tyrosine kinase
JP2013512543A JP5613323B2 (ja) 2010-05-26 2011-05-26 複数のチロシンキナーゼに対する阻害活性を有する抗炎症化合物およびこれを含む薬学的組成物
CN201180026042.7A CN102971327B (zh) 2010-05-26 2011-05-26 具有多种酪氨酸激酶抑制活性的抗炎化合物以及含有这些化合物的药物组成物
US13/699,970 US9062066B2 (en) 2010-05-26 2011-05-26 Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same
ES11786920.6T ES2647586T3 (es) 2010-05-26 2011-05-26 Compuesto antiinflamatorio que tiene actividad inhibidora contra múltiples tirosina cinasas, y composición farmacéutica que contiene el mismo
DK11786920.6T DK2578590T3 (da) 2010-05-26 2011-05-26 Anti-inflammatorisk forbindelse med inhibitorisk aktivitet mod flere tyrosinkinaser og farmaceutisk sammensætning indeholdende samme
KR1020127030670A KR101478302B1 (ko) 2010-05-26 2011-05-26 복수의 타이로신 카이네이즈에 대한 저해 활성을 가지는 항염증 화합물 및 이를 포함하는 약학적 조성물
EP11786920.6A EP2578590B1 (fr) 2010-05-26 2011-05-26 Composé anti-inflammatoire ayant une activité inhibitrice contre des tyrosine kinases multiples, et composition pharmaceutique contenant celui-ci
HUE11786920A HUE035589T2 (en) 2010-05-26 2011-05-26 An anti-inflammatory compound having an anti-tyrosine kinase inhibitory activity and a pharmaceutical composition containing it
PCT/KR2011/003873 WO2011149288A2 (fr) 2010-05-26 2011-05-26 Composé anti-inflammatoire ayant une activité inhibitrice contre des tyrosine kinases multiples, et composition pharmaceutique contenant celui-ci

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2010/003332 WO2011149126A1 (fr) 2010-05-26 2010-05-26 Composition pharmaceutique comprenant un composé anti-inflammatoire présentant une fonction d'inhibition de la tyrosine kinase

Publications (1)

Publication Number Publication Date
WO2011149126A1 true WO2011149126A1 (fr) 2011-12-01

Family

ID=45004106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/003332 WO2011149126A1 (fr) 2010-05-26 2010-05-26 Composition pharmaceutique comprenant un composé anti-inflammatoire présentant une fonction d'inhibition de la tyrosine kinase

Country Status (1)

Country Link
WO (1) WO2011149126A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492383B1 (en) * 1997-11-11 2002-12-10 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
WO2007056214A2 (fr) * 2005-11-02 2007-05-18 Cytovia, Inc N-alkyl-n-aryl-thienopyrimidin-4-amines et analogues en tant qu'activateurs de caspases et inducteurs d'apoptose et utilisation associee

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492383B1 (en) * 1997-11-11 2002-12-10 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
WO2007056214A2 (fr) * 2005-11-02 2007-05-18 Cytovia, Inc N-alkyl-n-aryl-thienopyrimidin-4-amines et analogues en tant qu'activateurs de caspases et inducteurs d'apoptose et utilisation associee

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOSCHELLI, D.H. ET AL.: "Inhibition of Src kinase activity by 7-[(2,4-dichloro-5-methoxyphenyl)-amino]-2-heteroaryl-thieno[3,2-b] pyridine-6-carbonitriles", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 15, 2005, pages 4681 - 4684 *

Similar Documents

Publication Publication Date Title
WO2012046030A3 (fr) Inhibiteurs de phosphodiestérase
WO2011162515A3 (fr) Nouveaux dérivés fusionnés de pyrimidine pour l'inhibition de l'activité tyrosine kinase
WO2008094737A3 (fr) Composés et compositions servant en tant qu'inhibiteurs de kinases
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
WO2011014795A3 (fr) Composés et compositions pouvant servir d'inhibiteurs de la kinase syk
WO2012021715A3 (fr) Formulations stables de linaclotide
WO2011113060A3 (fr) Composés antiviraux et procédés d'utilisation de ceux-ci
MX2010014041A (es) Una forma cristalina de posaconazol.
WO2013185082A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
WO2011149288A3 (fr) Composé anti-inflammatoire ayant une activité inhibitrice contre des tyrosine kinases multiples, et composition pharmaceutique contenant celui-ci
MX2018009861A (es) Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa.
WO2012101653A3 (fr) Compositions pharmaceutiques de mémantine à libération modifiée
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
WO2015015378A3 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
WO2014141210A3 (fr) Cellules souches de pulpe dentaire immatures multifonctionnelles et applications thérapeutiques
WO2011126250A3 (fr) Composition contenant un inhibiteur de pde5 pour l'atténuation des rides de la peau
WO2011141488A3 (fr) Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone
WO2011121576A3 (fr) Protéines et compositions immunogènes
WO2011159137A3 (fr) Nouvelle thio-urée ou nouveau dérivé d'urée, procédé permettant leur préparation, et composition pharmaceutique destinée à prévenir ou à traiter le sida, les contenant en tant que principe actif
WO2014160775A8 (fr) Compositions et méthodes de traitement de la malaria
AU2013208104A8 (en) Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof
WO2011149301A3 (fr) Composition comprenant l'extrait de physalis alkekengi var. francheti hort en tant que principe actif pour la prévention et le traitement de maladies inflammatoires
WO2011150457A3 (fr) Inhibiteurs de la prostaglandine d2 synthase hématopoïétique
WO2011088160A3 (fr) Nouveaux inhibiteurs de cyp17
MX344189B (es) Formulaciones de mazindol.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10852212

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 07.03.2013)

122 Ep: pct application non-entry in european phase

Ref document number: 10852212

Country of ref document: EP

Kind code of ref document: A1